This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

FDA Approves Incyte Myelofibrosis Drug

WILMINGTON, Del. ( TheStreet) --U.S. regulators approved a new medicine from Incyte (INCY - Get Report) to treat patients with myelofibrosis, a rare bone marrow disease.

Incyte's new drug, Jakafi, is the first approved therapy for myelofibrosis and the first approved drug to emerge from Incyte's labs. The U.S. Food and Drug Administration approval Wednesday came earlier than the expected decision date of Dec. 3.

Incyte shares were up $1.30, or 10%, to $13.90 in Wednesday trading following the announcement of Jakafi's approval.

Myelofibrosisis is a disorder in which abnormal bone marrow stem cells produce scar tissue that replaces healthy marrow. Patients with myelofibrosis suffer from anemia and enlarged spleens. Approximately 3,500 people in the U.S. are diagnosed with myelofibrosis annually and about one-third of these patients develop acute myeloid leukemia or bone marrow failure.

Jakafi, a pill taken twice a day, inhibits enzymes known as JAK1 and JAK2 believed to play a role in diseases like myelofibrosis that cause bone marrow cells to grow uncontrollably. So-called JAK inhibitors are also being studied against immune-related inflammatory diseases such as rheumatoid arthritis.

"Jakafi represents another example of an increasing trend in oncology where a detailed scientific understanding of the mechanisms of a disease allows a drug to be directed toward specific molecular pathways," said Richard Pazdur, FDA's director of the Office of Hematology and Oncology Products, in a statement. "The clinical trials leading to this approval focused on problems that patients with myelofibrosis commonly encounter, including enlarged spleens and pain."

Two phase III clinical trials demonstrated that treatment with Jakafi significantly reduced the spleen size and ameliorated disease symptoms in patients with myelofibrosis compared to treatment with best alternative care or a placebo.

"The availability of Jakafi is a significant medical advancement for people living with myelofibrosis, a debilitating disease," said Incyte CEO Paul Friedman, in a statement. "This milestone marks a tremendous achievement for Incyte because a scientific discovery from our research laboratories has become the first JAK inhibitor to reach the market and provide a clinical benefit to patients."

Incyte plans a commercial launch of Jakafi with partner Novartis (NVS - Get Report) next week.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
INCY $101.66 0.00%
NVS $102.46 0.00%
AAPL $124.75 0.00%
FB $80.78 0.00%
GOOG $524.05 0.00%


DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs